# Argos Therapeutics

Source: https://onco.cc/companies/argos-therapeutics/  
OnCo record `argos-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Argos was a North Carolina company whose personalised dendritic-cell vaccine rocapuldencel-T, made from each patient's own tumour RNA, failed the phase 3 ADAPT trial in kidney cancer and the company closed in 2019.

## Summary

Argos Therapeutics, founded in 1997 in Durham, North Carolina, built the Arcelis platform, which loaded a patient's dendritic cells with RNA amplified from their own tumour. Rocapuldencel-T (AGS-003) was tested with sunitinib in the phase 3 ADAPT trial in metastatic renal cell carcinoma; the trial was stopped for futility in 2017 and the company filed for bankruptcy in 2019. Its trials remain on ClinicalTrials.gov under Argos as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Argos Therapeutics, Inc.; Argos
- Tags: ctgov-sponsor
- HQ: Durham, NC
- Type: cell-therapy
- Website: http://www.argostherapeutics.com

## Sources

- Official website: http://www.argostherapeutics.com
- ClinicalTrials.gov: trials led by Argos Therapeutics, Inc.: https://clinicaltrials.gov/search?lead=Argos%20Therapeutics%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q30286762

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- technologies: [Dendritic cell vaccines](https://onco.cc/technologies/dendritic-cell-vaccines/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/argos-therapeutics.json